Company Overview - Carnival Corporation operates as a cruise and vacation company and is the largest cruise operator in the world, carrying nearly half of the global cruise guests [11] - The company is headquartered in Miami, FL, and operates in North America, Australia, Europe, and Asia [11] Investment Ratings - Carnival is currently rated as a 3 (Hold) on the Zacks Rank, with a VGM Score of A, indicating a solid overall performance [11] - The Growth Style Score for Carnival is B, forecasting a year-over-year earnings growth of 7.6% for the current fiscal year [12] Earnings Estimates - For fiscal 2026, two analysts have revised their earnings estimates upwards in the last 60 days, with the Zacks Consensus Estimate increasing by $0.02 to $2.42 per share [12] - Carnival has an average earnings surprise of +160%, suggesting strong performance relative to expectations [12] Investment Potential - With a solid Zacks Rank and top-tier Growth and VGM Style Scores, Carnival is recommended as a potential investment for growth investors [12]

Core Insights - Zacks Premium offers various tools to enhance stock market investment confidence and knowledge [1][2] Zacks Style Scores - Zacks Style Scores are indicators that rate stocks based on value, growth, and momentum methodologies, helping investors identify stocks likely to outperform the market in the next 30 days [3][4] - Each stock is rated from A to F, with A indicating the highest potential for outperformance [4] Value Score - The Value Style Score focuses on identifying undervalued stocks using financial ratios like P/E, PEG, and Price/Sales [4] Growth Score - The Growth Style Score emphasizes a company's financial health and future outlook, analyzing projected and historical earnings, sales, and cash flow [5] Momentum Score - The Momentum Style Score assesses stocks based on price trends and earnings outlook changes, helping investors capitalize on upward or downward price movements [6] VGM Score - The VGM Score combines all three Style Scores, providing a comprehensive indicator for investors who utilize multiple investing strategies [7] Zacks Rank - The Zacks Rank is a proprietary model that uses earnings estimate revisions to simplify portfolio building, with 1 (Strong Buy) stocks achieving an average annual return of +23.81% since 1988, significantly outperforming the S&P 500 [8][9] - There are over 800 top-rated stocks available, making it essential to use Style Scores to narrow down choices [9] Stock to Watch: Theravance Biopharma (TBPH) - Theravance Biopharma is a biopharmaceutical company focused on respiratory medicines, rated 2 (Buy) on the Zacks Rank with a VGM Score of A [12] - The company is particularly appealing to growth investors, with a Growth Style Score of A and a forecasted year-over-year earnings growth of 175% for the current fiscal year [13] - Recent upward revisions in earnings estimates and a strong average earnings surprise of +55.4% further enhance TBPH's investment appeal [13]

Core Viewpoint - BKV is a notable stock in the Oils-Energy sector, showing strong year-to-date performance compared to its peers, with a return of 16.9% against the sector average of 6.9% [4]. Company Performance - BKV has a Zacks Rank of 1 (Strong Buy), indicating a positive earnings outlook, with the consensus estimate for full-year earnings increasing by 33.1% in the past quarter [3]. - The stock has returned approximately 16.9% since the beginning of the year, outperforming the average return of 6.9% for Oils-Energy companies [4]. Industry Context - BKV is part of the Alternative Energy - Other industry, which includes 43 stocks and currently ranks 153 in the Zacks Industry Rank. This industry has seen a year-to-date gain of about 38.9%, indicating that BKV is slightly underperforming its industry [5]. - In contrast, Daqo New Energy, another stock in the Oils-Energy sector, has significantly outperformed with a year-to-date increase of 61% and a Zacks Rank of 2 (Buy) [4][5].

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.Zacks Premium includes access to the Zacks Style Scores as well. What are the Zacks Style Scores? Dev ...

Investors interested in Aerospace stocks should always be looking to find the best-performing companies in the group. ATI (ATI) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look at the stock's year-to-date performance to find out.ATI is a member of our Aerospace group, which includes 63 different companies and currently sits at #10 in the Zacks Sector Rank. The Zacks Sector Rank gauges the streng ...

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. AtriCure (ATRC) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.AtriCure is a member of our Medical group, which includes 946 different companies and cu ...

Core Viewpoint - The article discusses the reliability of brokerage recommendations and their influence on stock prices, specifically focusing on CSLM Acquisition Corp. (SPWR) and the implications of its average brokerage recommendation (ABR) of 1.67, which suggests a buy rating [2][5]. Brokerage Recommendation Analysis - CSLM Acquisition Corp. has an average brokerage recommendation (ABR) of 1.67, indicating a rating between Strong Buy and Buy, with 66.7% of the recommendations being Strong Buy from three brokerage firms [2]. - Despite the positive ABR, relying solely on this information for investment decisions may not be advisable, as studies indicate that brokerage recommendations often fail to guide investors effectively [5][11]. Analyst Bias and Recommendations - Analysts from brokerage firms tend to exhibit a strong positive bias in their ratings due to vested interests, with a ratio of five "Strong Buy" recommendations for every "Strong Sell" [6][11]. - This misalignment of interests suggests that brokerage recommendations may not provide reliable insights into future stock price movements [7][11]. Zacks Rank Comparison - The Zacks Rank, a proprietary stock rating tool, categorizes stocks from Strong Buy to Strong Sell and is based on earnings estimate revisions, which have shown a strong correlation with near-term stock price movements [8][12]. - The Zacks Rank for CSLM Acquisition Corp. is currently 3 (Hold), indicating a cautious stance, as the consensus estimate for the current year remains unchanged at -$0.45 [14][15]. Conclusion on Investment Worthiness - Given the unchanged consensus estimate and the Zacks Rank of 3, it may be prudent to exercise caution regarding the Buy-equivalent ABR for CSLM Acquisition Corp. [15].

Company Performance - Astera Labs, Inc. (ALAB) experienced a decline of 2.2% in its stock price, closing at $168.83, while the S&P 500 gained 0.46% [1] - Over the last month, ALAB shares increased by 16.83%, outperforming the Computer and Technology sector's gain of 4.54% and the S&P 500's gain of 4.22% [1] Upcoming Earnings - Analysts expect Astera Labs to report earnings of $0.51 per share, reflecting a year-over-year growth of 37.84% [2] - Revenue is projected to be $249.79 million, indicating a significant growth of 77.03% compared to the same quarter last year [2] Full Year Projections - For the full year, earnings are projected at $1.78 per share and revenue at $831.69 million, representing increases of 111.9% and 109.87% respectively from the previous year [3] Analyst Estimates - Changes in analyst estimates for Astera Labs are crucial as they reflect the shifting dynamics of short-term business patterns, with upward revisions indicating positive sentiment towards the company's operations [4] - The Zacks Rank system, which assesses these estimate changes, currently rates Astera Labs at 3 (Hold) [6] Valuation Metrics - Astera Labs holds a Forward P/E ratio of 97.16, significantly higher than the industry average of 29.41, suggesting that the company is trading at a premium [7] - The company has a PEG ratio of 1.78, compared to the Internet - Software industry's average PEG ratio of 1.85, indicating a favorable growth outlook [8] Industry Context - The Internet - Software industry, part of the Computer and Technology sector, has a Zacks Industry Rank of 53, placing it in the top 22% of over 250 industries [8] - The strength of individual industry groups is measured by the Zacks Industry Rank, with the top 50% rated industries outperforming the bottom half by a factor of 2 to 1 [9]

Company Performance - Doximity (DOCS) closed at $43.53, down 3.22% from the previous day's closing price, underperforming the S&P 500 which gained 0.46% [1] - The stock has decreased by 9.95% over the past month, while the Medical sector gained 1.59% and the S&P 500 increased by 4.22% [1] Upcoming Financial Results - Doximity is expected to report an EPS of $0.44, a decrease of 2.22% compared to the same quarter last year [2] - Revenue is projected to be $181.03 million, reflecting a 7.37% increase from the equivalent quarter last year [2] Fiscal Year Projections - For the entire fiscal year, earnings are projected at $1.56 per share, representing a 9.86% increase from the prior year [3] - Revenue for the fiscal year is estimated at $645.29 million, indicating a 13.13% increase from the previous year [3] Analyst Estimates and Revisions - Recent modifications to analyst estimates for Doximity indicate short-term business trends, with upward revisions suggesting positive sentiment towards the company's operations [4] - The Zacks Rank system, which incorporates these estimate changes, currently ranks Doximity at 3 (Hold) [6] Valuation Metrics - Doximity has a Forward P/E ratio of 28.75, which is a discount compared to the industry average Forward P/E of 46.25 [6] - The company has a PEG ratio of 1.52, significantly lower than the Medical Info Systems industry's average PEG ratio of 3.49 [7] Industry Context - The Medical Info Systems industry, part of the Medical sector, holds a Zacks Industry Rank of 102, placing it in the top 42% of over 250 industries [7] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [8]

Group 1: Stock Performance - V.F. (VFC) closed at $18.43, down 1.18% from the previous day, underperforming the S&P 500 which gained 0.46% [1] - Over the past month, V.F. shares have increased by 13.93%, outperforming the Consumer Discretionary sector's gain of 3.1% and the S&P 500's gain of 4.22% [1] Group 2: Earnings Expectations - The upcoming earnings report is expected to show EPS of $0.44, a decrease of 29.03% from the prior-year quarter, with projected net sales of $2.8 billion, down 1.21% from the year-ago period [2] - For the full year, analysts expect earnings of $0.72 per share and revenue of $9.43 billion, reflecting changes of -2.7% and -2.16% respectively from last year [3] Group 3: Analyst Estimates and Rankings - Recent changes to analyst estimates for V.F. indicate shifting business dynamics, with positive revisions suggesting analysts' confidence in the company's performance [4] - The Zacks Rank system, which ranges from 1 (Strong Buy) to 5 (Strong Sell), currently ranks V.F. at 3 (Hold), with a recent 0.39% increase in the Zacks Consensus EPS estimate [6] Group 4: Valuation Metrics - V.F. is currently trading at a Forward P/E ratio of 26.08, which is higher than the industry average of 18.33, indicating a premium valuation [7] - The company has a PEG ratio of 1.87, compared to the industry average PEG ratio of 3.08, suggesting a more favorable growth outlook relative to its valuation [8] Group 5: Industry Context - The Textile - Apparel industry, part of the Consumer Discretionary sector, holds a Zacks Industry Rank of 84, placing it in the top 35% of over 250 industries [8] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1, highlighting the competitive positioning of the industry [9]